LEADING THE WAY IN CANCER THERAPIES OF THE FUTURE

Despite all efforts in cancer prevention and significant progress in the availability of new treatment options in the last decade, incidence and global mortality rates are projected to continue to rise.

Our proprietary EPiC cell therapy platform for silencing intracellular IO targets enables rapid treatment of patients using their own fresh immune cells in an out-patient setting. Once validated in a clinical setting, this novel concept will allow access to and treatment for indications previously not addressable by cell therapy.

Find out more ABOUT US

THREE ELEMENTS OF OUR SUCCESS

EPiC cell therapy platform for solid and hematological cancers
Small molecule IO project
Innovation Hub driving the expansion of our pipeline

More about our SCIENCE

OUR INNOVATIVE IMMUNO-ONCOLOGY PIPELINE

APN401

is a TUMOR-REACTIVE, autologous cell therapy with a highly specific siRNA-based activation of white blood cells. Currently in clinical Phase 1 testing in patients with various solid tumors.

INV441

is a TUMOR-ASSOCIATED cell therapy with a highly specific siRNA-based activation of local immune cells known as Tumor Infiltrating Lymphocytes (TILs). Currently in pre-clinical development.

INV501

is a TUMOR-SPECIFIC novel small molecule for immune activation upon oral application. Currently in pre-clinical development.

Learn more about our PIPELINE

SCIENCE NEVER STOPS

WE ARE HIRING

Making a HUGE IMPACT on patient’s lives keeps us motivated. At invIOs, we are making a contribution to PEOPLE’S WELLBEING. We strive every day to improve the lives of our patients with next-generation technologies and individual therapies.

Working at invIOs, you could contribute to solving some of the toughest challenges in treating cancer. We at invIOs think that our people are our most important asset.